What to expect your first month on a GLP-1, week by week

First, what month one is actually for

Both of the major GLP-1 medications start far below their full dose, on purpose:

• Wegovy (semaglutide) starts at 0.25 mg once weekly for weeks 1–4. The label is explicit that this is a starter dose, not a treatment dose — the full schedule steps up every four weeks (0.5 → 1.0 → 1.7 → 2.4 mg), reaching the standard maintenance dose at week 17.
• Zepbound (tirzepatide) starts at 2.5 mg once weekly for weeks 1–4, which the label likewise describes as for “treatment initiation” only, before moving to 5 mg and then upward in 2.5 mg steps.

Why so slow? One reason, straight from the prescribing information: gradual escalation reduces gastrointestinal side effects. Your digestive system adapts to these medications; the titration schedule is that adaptation, formalized.

This matters for your expectations. If you’re hoping month one delivers dramatic weight loss, you’ll likely be disappointed — and if you’re terrified month one will be miserable, the odds are better than you think. Both effects, good and bad, ramp with the dose. (If you’re still deciding which medication, our Wegovy vs. Zepbound comparison covers the head-to-head trial data.)

Week 1: the first injection

The practical part is genuinely easier than most people fear. Both medications come as a once-weekly injection with a fine, short needle into the fatty tissue of the stomach, thigh, or upper arm — any day, any time, with or without food. Pick a day you’ll remember and keep it; consistency matters more than timing.

Needle anxiety deserves its own sentence, because it’s the single most common beginner fear. When we analyzed a 400-comment “I’m scared to start” thread in the r/Zepbound community, nearly half of the responses we reviewed (84 of 185) were experienced users saying some version of it’s far easier and less painful than you’re imagining — many can’t feel the auto-injector at all and listen for the click instead. People who nearly faint at blood draws report managing this fine.

A few things first-weekers consistently wish they’d known:

• You may feel nothing at all. At a starter dose, plenty of people notice no appetite change and no side effects in week one. That is not a sign the medication “isn’t working” — it isn’t supposed to be doing much yet. (In a 440-comment community thread asking for reassurance about side effects, “minimal or none” was the single largest group among the responses we analyzed — 65 of 184.)
• Some people notice appetite changes within days. The other common report: meals start feeling “done” sooner, and the background mental chatter about food — what patient communities call food noise — gets quieter. Both are normal; so is neither.
• Rotate injection sites week to week (the manufacturer instructions recommend it) to avoid soreness.

Weeks 2–3: if side effects come, this is the shape they take

Let’s use the actual numbers, because vague warnings are scarier than data. These are from the FDA labels’ adult trial tables, collected over the entire trial period (not just month one) — at doses far higher than you’re on right now:

In practice, the common month-one experience is mild and intermittent: queasiness on injection day or the day after, feeling full unusually fast, burping, constipation, or loose stools. The widely shared coping basics — eat smaller meals, eat slowly, go easy on greasy and very rich food, stay ahead on water — come straight from the manufacturers’ own patient guidance and are echoed across patient communities.

Two practical notes the brochures undersell:

• Constipation sneaks up. Nausea gets the headlines, but a quarter of Wegovy patients reported constipation. Fluid, fiber, and movement early beat fixing it later.
• “Fast fullness” is a feature that feels like a bug. Stopping mid-meal because you’re simply done is the medication working — plan smaller portions so it doesn’t register as waste or failure.

Week 4: the scale, and what counts as progress

At a starter dose, trial data suggests early weight change is real but modest — low single digits of body weight percentage, often partly water. The dramatic averages you’ve seen in headlines (15%+ on semaglutide, 20%+ on tirzepatide) are one- to one-and-a-half-year results at full maintenance doses.

Better month-one success markers than the scale:

• You’ve kept your weekly injection schedule.
• You’ve found an eating rhythm that doesn’t fight the medication.
• You’ve started some resistance work — research on GLP-1s notes that a portion of weight lost is lean mass, so clinicians commonly recommend protein and strength exercise from day one. (This matters more, not less, if you’re over 60.)
• You know what your month-two dose is and have the refill sorted — pharmacy stock and insurance paperwork, not side effects, are the most common early disruptions patients report. Our cost calculator and PA letter templates exist for exactly this.

When it’s not “normal adjustment”: call your prescriber

Most first-month discomfort is the ordinary kind. The following are not — these come from the labels’ warnings sections, and they’re the reason this article can’t replace your own clinician:

• Severe, persistent abdominal pain, especially radiating to your back, with or without vomiting — the labels warn this can signal pancreatitis. Stop guessing and call.
• Pain in the upper right abdomen, fever, or yellowing skin/eyes — possible gallbladder problems, which occur more often on these medications.
• Vomiting or diarrhea you can’t keep ahead of — dehydration on these drugs has been associated with kidney injury; persistent inability to keep fluids down is a same-day call.
• Signs of a serious allergic reaction (swelling of face or throat, trouble breathing) — emergency care, immediately.
• If you also take insulin or a sulfonylurea for diabetes: low-blood-sugar episodes (shakiness, sweating, confusion) — your other medications may need adjusting, which is a prescriber conversation, ideally before your first dose.

One more for completeness: both labels carry a boxed warning about thyroid C-cell tumors seen in rodents, and neither drug should be used by anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 — your prescriber should have screened for this already.

Month two and beyond: the road ahead

Here’s the standard escalation path, so nothing surprises you (your prescriber may go slower — the Wegovy label explicitly allows pausing an escalation step for four weeks if a dose isn’t sitting well, and Zepbound’s requires at least four weeks per step):

*Zepbound’s steps above 5 mg are “as needed and tolerated” — 5 mg, 10 mg, and 15 mg are all approved maintenance doses, and plenty of people stay below the max.

Each step up can re-run a smaller version of the adjustment you just made — the week-after-increase queasiness pattern repeats, then fades. By the time you reach maintenance, you’ll have done it several times and know your own playbook.

Frequently asked questions